

Oculoplastic Surgery

Case Report

Prostaglandin-Associated Periorbital Lipodystrophy in Cosmetic Eyelid Surgery: A Novel Cause of Facial Asymmetry

Kian Eftekhari, MD; Mark D. Mifflin, MD;
and Richard L. Anderson, MD, FACS

Aesthetic Surgery Journal
2015, 1–3
© 2015 The American Society for
Aesthetic Plastic Surgery, Inc.
Reprints and permission:
journals.permissions@oup.com
DOI: 10.1093/asj/sjv184
www.aestheticsurgeryjournal.com
OXFORD
UNIVERSITY PRESS

Abstract

A 70-year-old woman presented to our practice with profound ptosis of the left upper eyelid and notable asymmetry of the periocular area. On examination, she was noted to have significant atrophy of the periocular tissues on the left side, with lower eyelid retraction. These features were present but less severe on the right side. Upon further questioning, she stated that she had cataract surgery on the left side that was complicated by a high intraocular pressure and required subsequent secondary surgery. She had taken a prostaglandin eyedrop for many months after her cataract surgery to keep the eye pressure low. Recently, a newly recognized adverse effect of prostaglandin eyedrops has been described in the ophthalmic literature in which patients develop periorbital lipodystrophy. This case emphasizes that this may occur unilaterally in patients taking the eyedrop in only one eye, and should be recognized prior to considering functional and aesthetic surgery of the periocular area.

Level of Evidence: 5

Accepted for publication August 18, 2015.



Evaluation of the cosmetic surgery patient requires careful attention to subtle differences in facial aging and, especially, taking note of facial asymmetry. This is especially true in eyelid surgery as patients often present with dermatochalasis or ptosis and desire a correction to establish a more symmetric shape to the palpebral fissure. Identifying facial asymmetry before surgery is of paramount importance in preoperative planning to address symmetry and to set realistic expectations with the patient.

Recently, there have been reports in the ophthalmology literature of periorbital hollowing, or lipodystrophy, with the increasing use of eyedrops to treat ocular hypertension or glaucoma that contain a prostaglandin analogue as the active ingredient.¹ These medications are known to cause hypertrichosis, hyperpigmentation, meibomian gland dysfunction, horizontal eyelid shortening, lid retraction, and lipodystrophy.^{1–3} They have recently been used commercially to increase eyelash length (bimatoprost, Latisse, Allergan Inc., Irvine, CA). Recent reports

have demonstrated severe atrophy of the periorbital fat has been noted to occur with the long-term use of these agents, although in some cases it may be reversible.^{4,5} It is not known exactly why this occurs, but it may involve blockade of the PPARγ pathway which is involved in adipogenesis.^{6–8} While this fat atrophy is problematic in most patients, we have postulated that it may have potential use in conditions such as thyroid eye disease in the future.

Dr Eftekhari is a fellow and Dr Anderson is an oculoplastic surgeon in private practice in Salt Lake City, UT, USA. Dr. Mifflin is a Clinical Professor of Ophthalmology and Fellowship Director in Corneal Surgery, John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA.

Corresponding Author:

Dr Kian Eftekhari, 1002 E. South Temple, Suite 308, Salt Lake City, UT 84102, USA.
E-mail: kianef@gmail.com

CASE REPORT

A 70-year-old woman presented to our clinic in October 2014 with a droopy left upper eyelid and dry eyes. On examination, she was noted to have mild dermatochalasis but severe involutional ptosis of the left upper eyelid and also a dermatochalasis and ptosis of the right upper eyelid. She was also noted to have bilateral lower eyelid retraction and confluent staining of the cornea indicating dry eyes. Her past ocular history included cataract surgery on both sides, but on the left eye she had a complicated initial surgery in which the posterior capsule of the lens was violated, which required a second surgery in which she underwent anterior vitrectomy and anterior chamber intraocular lens placement. She reported that her intraocular pressure had been as high as 50 mm Hg after cataract surgery (normal range, 10 to 21 mm Hg) and that she required travoprost prostaglandin eyedrops postoperatively for over six months to lower the pressure. Prior to surgery, we noted significant periorbital lipodystrophy on the left side with a deep supratarsal sulcus and asymmetric effacement of the junction between the nasal sidewall and a deep tear trough causing a hollow appearance (Figure 1A).

The patient underwent upper eyelid levator advancement surgery to correct her ptosis and also lateral canthal tightening and midface elevation to address the lower eyelid retraction on both sides. At the time of surgery, the orbital septum was opened to address the upper eyelid fat pads and the left upper eyelid fat pad was noted intraoperatively to be significantly atrophied when compared to the right (Figure 1B). In order to improve symmetry, she underwent conservative fat removal and sculpting on the right side but no fat removal on the left side. She also underwent upper punctal occlusion to close her tear ducts, and elected to have transpalpebral removal of the corrugator and depressor superciliaris muscle to reduce the furrowing of her eyebrows. At two months postoperatively, she had

improvement in the upper eyelid ptosis, an improved contour to the lower eyelid with an upward tilt at the lateral canthi, relief of her symptoms from dry eye, and improved symmetry (Figure 1C).

DISCUSSION

Periorbital lipodystrophy secondary to prostaglandin use has received increasing attention in the ophthalmology and ophthalmic plastic literature since it was first described in 2008.¹⁻³ The existing literature has focused on the changes that occur in the eyelids and periorbital tissues, and other authors have shown striking examples of unilateral disease that can give the appearance of severe facial asymmetry. To this point, the existing literature has focused on the clinical manifestations of this disease. We present a unique case in which we noted changes preoperatively but also intraoperatively demonstrated a difference in the amount of pre-aponeurotic fat. It is not possible to prove that this difference was directly caused by the prostaglandin analogue, but as is often the case in the field of facial plastic surgery, we relied on our observation of the asymmetry as well as the clinical history to infer that the changes may have been secondary to the medication-induced lipodystrophy. This finding has potential interest for all eyelid surgeons and is a notable finding in the context of the growing literature on this topic.

CONCLUSION

Noting facial asymmetry is critical during the evaluation of the cosmetic eyelid surgery patient. As use of eyedrops containing prostaglandin analogues has increased in the general population, it is important for the facial plastic surgeon to be aware of the side effect of periorbital lipodystrophy in these patients. This is especially important if the patient is using the medication unilaterally, which can



Figure 1. (A) Preoperative photograph of a 70-year-old woman showing bilateral dermatochalasis but more prominent on the right side, severe left upper eyelid ptosis with a deep supratarsal sulcus, and asymmetric effacement of the junction between the nasal sidewall and a deep tear trough causing a hollow appearance; (B) intraoperatively, showing larger pre-aponeurotic fat on the right side as compared to the left; (C) at two months postoperatively, the patient had improvement in the upper eyelid ptosis, an improved contour to the lower eyelid with less scleral show, and improved symmetry.

affect the surgical planning and, if ignored, will lead to unsatisfactory outcomes after surgery.

Disclosures

The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.

Funding

The authors received no financial support for the research, authorship, and publication of this article.

REFERENCES

1. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. *Ophthalmol Plast Reconstr Surg*. 2008;24(4):302-307.
2. Custer PL, Kent TL. Observations on prostaglandin orbitopathy. *Ophthalmol Plast Reconstr Surg*. 2015. [Epub ahead of print] doi: 10.1097/IOP.0000000000000431.
3. Sira M, Verity DH, Malhotra R. Topical bimatoprost 0.03% and iatrogenic eyelid and orbital lipodystrophy. *Aesthet Surg J*. 2012;32(7):822-824.
4. Aydin S, Işikligil I, Tekşen YA, Kir E. Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature. *Cutan Ocul Toxicol*. 2010;29(3):212-216.
5. Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. *Jpn J Ophthalmol*. 2011;55(1):22-27.
6. Fujimori K. Prostaglandins as PPAR γ modulators in adipogenesis. *PPAR Res*. 2012;2012:527607.
7. Serrero G, Lepak NM. Prostaglandin F $_{2\alpha}$ receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. *Biochem Biophys Res Commun*. 1997;233(1):200-202.
8. Silvestri C, Martella A, Poloso NJ, et al. Anandamide-derived prostamide F $_{2\alpha}$ negatively regulates adipogenesis. *J Biol Chem*. 2013;288(32):23307-23321.